AstraZeneca Plc. AZN said its Phase 3 I CAN trial evaluating Ultomiris (ravulizumab) in adults with immunoglobulin A ...

(Alliance News) - AstraZeneca PLC on Monday announced positive results from the Vista and Solstice phase IIb trials of ...

A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to other ...

AstraZeneca PLC (NYSE:AZN) is one of the best stocks to buy now for long term growth. AstraZeneca PLC (NYSE:AZN) reported on ...

AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...

AstraZeneca Plc AZN on Tuesday reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4 ...

This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical ...

AstraZeneca (AZN) climbed 3.1% as Bernstein reaffirms outperform rating, citing non-oncology portfolio as undervalued driver ...

View AstraZeneca PLC AZN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

May 2026Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer Recommendation based on SERENA-6 Phase III trial ...

AstraZeneca Plc expects profit to grow further this year, boosted by sales of its cancer drugs as it works to offset a patent expiry of a blockbuster diabetes medicine. Earnings per share, excluding ...